Applied Molecular Evolution Inc. (AME) seems to be in the right place, with the right technology, at the right time--a beneficiary of Big Pharma's current search for ways to short-cut the discovery process.
In the last three months, AME received initial product development milestones from two of its deals and filed an IND on its own lead product candidate, a humanized MAb designed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?